Skip to content

Clinical and Mechanistic Study of 14-3-3ß Mediating Trophoblast Involvement in Preeclampsia

Clinical and Mechanistic Study of 14-3-3ß Mediating Trophoblast Involvement in Preeclampsia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124329
Enrollment
Unknown
Registered
2026-05-11
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Interventions

Sponsors

The First Affiliated Hospital of Shihezi University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: The normal pregnancy group consisted of naturally conceived singleton pregnancies. The PE group was defined according to the expert consensus in the "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy (2020)." It includes new-onset hypertension after 20 weeks of gestation (systolic blood pressure >=140 mmHg and/or diastolic blood pressure >=90 mmHg) accompanied by proteinuria (urinary protein quantification >0.3 g/24 h, or urinary protein/creatinine ratio >=0.3, or random urine protein >=(+) [measurement method when protein quantification is not performed]); or no proteinuria but with involvement of any one of the following organs or systems: major organs such as heart, lungs, liver, kidneys, or abnormalities in the hematologic, digestive, or nervous systems, or placental-fetal involvement. Preeclampsia can also occur postpartum.

Exclusion criteria

Exclusion criteria: 1) Fetal genetic abnormalities, chromosomal malformations; 2) Infections such as chorioamnionitis, sepsis, etc.; 3) Harmful physical or chemical exposures during pregnancy; 4) Other diseases related to pregnancy complications (e.g., chronic hypertension and kidney disease); 5) Multiple pregnancies (>=2 fetuses), including cases after multifetal pregnancy reduction or with the death of one fetus;

Design outcomes

Primary

MeasureTime frame
Serum 14-3-3ß protein;

Secondary

MeasureTime frame
Placental 14-3-3ß protein;

Countries

China

Contacts

Public ContactGu Yajuan

The First Affiliated Hospital of Shihezi University

2584049853@qq.com+86 187 0309 6536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026